Base editing for sickle cell

Sickle cell disease warps red blood cells by changing adult hemoglobin, and one new gene-editing approach tries to flip patients back to the fetal version that does not sickle. (pubmed.ncbi.nlm.nih.gov) That approach, ristoglogene autogetemcel, or risto-cel, base-edits a patient’s own blood-forming stem cells outside the body. It makes precise A-to-G DNA letter changes in the HBG1 and HBG2 promoters so the BCL11A repressor can no longer keep fetal hemoglobin switched off. (pubmed.ncbi.nlm.nih.gov) (beamtx.com) In the ongoing Phase 1/2 BEACON trial, the study is testing a single dose of those edited autologous CD34-positive hematopoietic stem and progenitor cells in people with severe sickle cell disease and vaso-occlusive crises. ClinicalTrials.gov lists the trial as active, not recruiting, with an estimated enrollment of 15 and primary completion in February 2028. (clinicaltrials.gov) The treatment process is still intensive. Patients receive plerixafor to mobilize stem cells into the blood, undergo CD34-positive cell collection, then get busulfan myeloablative conditioning before the edited cells are infused back. (cancernetwork.com) (clinicaltrials.gov) The reason researchers are chasing fetal hemoglobin is straightforward: babies naturally make it, and it does not form the rigid fibers that drive sickling. People who keep higher fetal hemoglobin into adulthood usually have milder disease. (beamtx.com) (pubmed.ncbi.nlm.nih.gov) Base editing differs from older CRISPR cuts by swapping one DNA letter for another without making a full double-strand break. In lab work published in 2023, an adenine base editor produced higher and more uniform fetal hemoglobin than two Cas9 cutting strategies aimed at the same broad goal. (pubmed.ncbi.nlm.nih.gov) Beam said on April 1, 2026 that interim BEACON data were published in The New England Journal of Medicine. The company said 31 treated patients were included in the analysis as of an August 6, 2025 cutoff, with fetal hemoglobin sustained above 60% and no reported severe vaso-occlusive crises after engraftment. (investors.beamtx.com) That is a larger and later snapshot than the company’s June 2025 European Hematology Association presentation, which reported safety and efficacy data for 17 patients ages 18 to 34. The trial record and conference materials also show the program is aimed at patients with severe disease rather than the broader sickle cell population. (beamtx.com) (clinicaltrials.gov) Prime editing is part of the same family of tools, but it is built to write longer or more complex DNA changes than base editing. A 2025 Blood paper showed prime editing could install multiple fetal-hemoglobin-boosting mutations in globin promoters in hematopoietic cells, but that work remained preclinical. (ashpublications.org) For now, the nearer-term story in sickle cell is not a pill or an injection. It is a one-time transplant-style procedure that uses precise DNA letter changes to keep fetal hemoglobin on after birth. (clinicaltrials.gov) (pubmed.ncbi.nlm.nih.gov)